NEUROCRINE BIOSCIENCES INC
For the period ended Sep 30, 2026. Filed Nov 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 2, 2026
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in millions, except per share data) | September 30,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $641.5 | $713.0 |
| Available-for-sale debt securities | 96.4 | 767.4 |
| Accounts receivable | 957.3 | 686.8 |
| Inventory | 66.1 | 69.0 |
| Prepaid expenses | 212.4 | 170.7 |
| Other current assets | 34.5 | 115.8 |
| Total current assets | 2,008.2 | 2,522.7 |
| Noncurrent inventory | 177.7 | — |
| Noncurrent available-for-sale debt securities | 51.8 | 1,063.0 |
| Right-of-use assets | 437.2 | 455.4 |
| Equity investments | 95.0 | 120.8 |
| Property and equipment, net | 92.2 | 89.8 |
| Intangible assets, net | 2,191.0 | 4.7 |
| Goodwill | 500.6 | 6.1 |
| Deferred tax assets | 11.8 | 320.3 |
| Other noncurrent assets | 61.9 | 48.7 |
| Total assets | $5,627.4 | $4,631.5 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable and accrued liabilities | $923.4 | $674.3 |
| Other current liabilities | 61.2 | 69.1 |
| Total current liabilities | 984.6 | 743.4 |
| Deferred tax liabilities | 105.0 | — |
| Noncurrent operating lease liabilities | 392.3 | 415.3 |
| Other noncurrent liabilities | 266.8 | 219.7 |
| Total liabilities | 1,748.7 | 1,378.4 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5.0 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 220.0 shares authorized; 101.3 and 100.1 shares issued and outstanding, respectively | 0.1 | 0.1 |
| Additional paid-in capital | 3,035.8 | 2,792.2 |
| Accumulated other comprehensive income | 4.4 | 13.1 |
| Retained earnings | 838.4 | 447.7 |
| Total stockholders’ equity | 3,878.7 | 3,253.1 |
| Total liabilities and stockholders’ equity | $5,627.4 | $4,631.5 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.